Us2.ai co-founder and Non-Executive Head of Medical Affairs, Dr. Carolyn Lam, has been named a recipient of the 2026 Women As One Mentorship Award, sponsored by Alnylam Pharmaceuticals. She is one of only six recipients globally recognised through this award, which supports research at the intersection of artificial intelligence, equity, and the detection and diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM).
ATTR-CM remains one of the most underdiagnosed conditions in cardiovascular medicine, with women bearing a disproportionate burden of this diagnostic gap. Current diagnostic thresholds are largely derived from male populations, contributing to systematic under-recognition of the disease in women. Prof. Lam's award-winning work directly addresses this inequity, exploring how AI can advance equitable detection and improve outcomes for underserved patient populations.
As co-founder of Us2.ai and the scientific lead behind our cardiac amyloidosis AI detection platform, Dr. Lam brings a uniquely powerful combination of clinical expertise and AI implementation experience to this work. Us2.ai's dual-approach AI system for cardiac amyloidosis detection, the first of its kind, is FDA-cleared and CE-marked for clinical use, and has been validated across globally diverse patient populations.
Us2.ai congratulates Dr. Lam on this well-deserved recognition. Her commitment to ensuring that no patient is missed, regardless of sex, ethnicity, or geography, is at the core of what we build towards every day.